In general, the cardioprotective effects of GLP-1R agonists and tirzepatide are directly supported by findings from a recent meta-analysis by Stefanou et al., who found that these drugs reduce the risk of major adverse cardiovascular events (MACE) and all-cause mortality in patients with obesity [161]. This evidence concerns the gene GLP1R and obesity disorder.